Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.56 |
| ▸ | MMP3 | P08254 | 9/20 | 0.56 |
| ▸ | MMP9 | P14780 | 5/20 | 0.55 |
| ▸ | MMP1 | P03956 | 4/20 | 0.55 |
| ▸ | MMP14 | P50281 | 3/20 | 0.55 |
| ▸ | MMP13 | P45452 | 6/20 | 0.43 |
| ▸ | USP5 | P45974 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6586370 | 0.98 | MMP2 (0.56) | MMP2MMP3MMP9MMP1MMP14 | |
| SCHEMBL6586955 | 0.94 | MMP2 (0.54) | MMP2MMP3MMP9MMP1MMP14 | |
| SCHEMBL6585463 | 0.93 | MMP2 (0.53) | MMP2MMP3MMP9MMP1MMP14 | |
| SCHEMBL6433872 | 0.92 | MMP2 (0.55) | MMP2MMP3MMP9MMP1MMP14 | |
| SCHEMBL6433867 | 0.92 | MMP2 (0.55) | MMP2MMP3MMP9MMP1MMP14 | |
| SCHEMBL6433864 | 0.92 | MMP2 (0.55) | MMP2MMP3MMP9MMP1MMP14 | |
| SCHEMBL6587738 | 0.91 | MMP2 (0.53) | MMP2MMP3MMP9MMP1MMP14 | |
| SCHEMBL6583780 | 0.91 | MMP2 (0.54) | MMP2MMP3MMP9MMP1MMP14 | |
| SCHEMBL6586632 | 0.90 | MMP2 (0.52) | MMP2MMP3MMP9MMP1MMP14 | |
| SCHEMBL6965267 | 0.88 | MMP2 (0.51) | MMP2MMP3MMP9MMP1MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036062-B1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LTD (GB) | 2004-01-02 | — | — | EP | claimed |
| US-6495568-B1 | TREATMENT OF TISSUE ULCERATION, WOUND REPAIR AND SKIN DISEASES | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | claimed |
| EP-1036062-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | Pfizer Limited (GB) | 2000-09-20 | — | — | EP | claimed |
| WO-1999029667-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LIMITED (GB) | 1999-06-17 | — | — | WO | claimed |
| EP-1036062-B1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LTD (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-6495568-B1 | TREATMENT OF TISSUE ULCERATION, WOUND REPAIR AND SKIN DISEASES | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1036062-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | Pfizer Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999029667-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |